OS in patients with AH-MCL, including AH-DN and AH-t. (A) Median survival after diagnosis was 33 months. This included all patients with AH-MCL. (B) Median survival was significantly longer in patients aged <72 years (43 months) compared with those aged ≥72 years (11 months) (P < .001). The cutoff point of 72 years was based on classification and regression tree analysis. (C) Median survival was significantly inferior in patients with poor Eastern Cooperative Oncology Group performance status compared with patients with good performance status at the time of diagnosis of AH-MCL (P < .001). (D) Median survival was significantly shorter in patients with a platelet count <63 000 × 10³/μL (9 months) vs ≥63 000 × 10³/μL (44 months) (P < .001). The cutoff point of 63 000 × 10³/μL was based on classification and regression tree analysis. (E) Median survival was significantly longer in patients who achieved CR after first-line treatment following the diagnosis of AH-MCL (72 months) compared with those patients who did not achieve CR (13 months) after first-line therapy (P < .001). (F) Median survival was not statistically different in patients with blastoid vs pleomorphic variants; however, there was a clear trend of better survival in the blastoid category (median survival, 34 vs 22 months in blastoid vs pleomorphic, respectively; P = .640).